J&J Fined $1.2 Billion in Risperdal Case
A judge in Arkansas ordered Johnson & Johnson and a subsidiary to pay more than $1.2 billion in fines on Wednesday, a day after a jury found that the companies had minimized or concealed the dangers associated with their antipsychotic drug Risperdal.
The fine, which experts said ranked among the largest on record for a state fraud case involving a drug company, is the most recent in a string of legal losses for Johnson & Johnson related to
TriMark Legal Funding provides Risperdal pre settlement funding to injured plaintiffs nationwide.
This post originally appeared here: https://www.nytimes.com/2012/04/12/business/drug-giant-is-fined-1-2-billion-in-arkansas.html
Click here to see the full original article.